INSP — Inspire Medical Systems, Inc.

Inspire Medical Systems, Inc. (INSP) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Increased 1.6% year-over-year to $204.6 million, primarily due to market penetration.
• Operating Margin: Improved, driven by a higher sales mix of Inspire V systems.
• Adjusted EPS: Reported a loss of $0.39; adjusted diluted EPS was $0.10.
• Operating Cash Flow: Improved to $12.8 million, up $20 million from the prior year.
• Cash Position: Ended the quarter with $400 million in cash and investments, no debt.
• Effective Tax Rate: Increased to 571.2% due to stock-based compensation; adjusted effective tax rate was 25.7%.

2. Strategic Updates and Business Highlights

• Coding and Reimbursement: Ongoing efforts to establish consistent coding for Inspire V procedures. A new CPT code for a single-lead Inspire system is anticipated to be effective January 1, 2028.
• WISER Program: A government initiative creating prior authorization delays for Medicare cases in six states, impacting revenue.
• Patient Access: Increased support for customers through education on prior authorization and billing processes.
• Clinical Trials: Upcoming presentations at the SLEEP conference will showcase data on Inspire V and cardiovascular outcomes, enhancing the product's clinical credibility.
• Salesforce Adjustments: Territory management is being optimized with a focus on existing accounts while also opening new centers.

3. Forward Guidance and Outlook

• Revised Revenue Outlook: Projected full-year revenue now between $825 million and $875 million, reflecting ongoing coding and reimbursement challenges.
• Impact of Challenges: Estimated revenue impact from coding and reimbursement issues and the WISER program is expected to be $120 million to $150 million for the year.
• Profitability Metrics: Adjusted operating margin expected to be 2% to 4%, with diluted EPS revised to a range of $0.07 to $0.62.
• Second Quarter Expectations: Anticipated adjusted operating loss of $10 million to $15 million, with expectations for sequential improvement in the latter half of the year.

4. Bad News, Challenges, or Points of Concern

• Revenue Headwinds: Coding and reimbursement uncertainty, along with the WISER program, are significant challenges affecting revenue.
• Prior Authorization Delays: The WISER program has created delays in traditional Medicare procedures, impacting revenue generation.
• GLP-1 Therapies: Increasing prevalence of GLP-1 therapies may be contributing to a lag in patient referrals for Inspire therapy.
• Salesforce Adjustments: A contraction in U.S. territory count raises concerns about the effectiveness of the sales strategy during a critical time.

5. Notable Q&A Insights

• Reimbursement Confidence: Management is optimistic about improving reimbursement practices as centers gain experience with the new coding methodologies.
• Patient Pipeline: Efforts are being made to keep track of patients in the pipeline to ensure they do not lose interest due to delays.
• Impact of Competition: While a competitor has launched a similar product, current challenges in coding and reimbursement are overshadowing competitive pressures.
• Future Growth: Management believes that with improved coding clarity and successful navigation of the WISER program, growth can resume before the new CPT code is implemented in 2028.

In summary, while Inspire Medical Systems demonstrated some revenue growth and maintained a strong cash position, significant challenges related to coding, reimbursement, and the WISER program are impacting their outlook for 2026. The company is focused on addressing these issues while continuing to support patient access and clinical validation of their therapies.